

SAFIRA™

GIVING ANESTHESIOLOGISTS CONTROL

A groundbreaking new technology
for regional anesthesia



medovate.co.uk

MEDOVATE
Developing Innovation

A groundbreaking new technology for regional anesthesia

SAFIRA™ - SAFeR Injection for Regional Anesthesia.


A revolutionary new technology.

SAFIRA™ makes regional anesthesia a one person procedure, putting control in the hands of the anesthesiologist.

A unique engineered in safety solution monitors and limits injection pressure.

This improves patient safety by reducing the risk of patient nerve damage resulting from the regional anesthesia procedure.

SAFIRA™ helps promote better outcomes for both professionals and patients.



SAFIRA™ reduces the risk of nerve damage and improves patient outcomes¹

A clinician led approach

Regional anesthesia is currently a two-person procedure

One anesthesiologist holds the ultrasound scanner to guide the needle tip placement, while a second operator injects the anesthetic at the required pressure.

SAFIRA™ transforms regional anesthesia into a one-person procedure

It allows a single operator, an anesthesiologist, to conduct the whole regional block at safer pressures.

Anesthetic solutions are often injected at high pressure

This can cause nerve damage, serious nerve damage occurs in up to 1% of procedures and transient nerve damage in up to 8% of cases.^{2,3}

SAFIRA™ helps to prevent injection at unsafe pressures


A built in system helps to prevent injection at pressures above 20psi which reduces the risk of incidences of transient or serious nerve damage occurring as a result of the regional anesthesia procedure.

How to use SAFIRA™


SAFIRA™ is intended for use by trained clinicians to administer local anesthetic below a specified pressure threshold to a target nerve bundle for regional anesthesia.

SAFIRA™ consists of 3 separate components:


- 1 Sterile Syringe**
(Product reference: 900016)
- 2 Driver**
(Product reference: 900029)
- 3 Foot Pedal**
(Product reference: 900044)



The Sterile Syringe is connected to the SAFIRA™ driver unit



SAFIRA™ has been developed in compliance with international standards and has FDA clearance



SAFIRA™ is engineered to help prevent injection above 20psi



To view our video on how to use SAFIRA™ please go to:
www.medovate.co.uk/products

MEDOVATE

Developing Innovation

Medovate is a dynamic medical device company dedicated to the development and commercialization of innovative medical technologies created within the UK National Health Service (NHS) and beyond.

We accelerate innovative medical technologies to market for the benefit of patient care and healthcare delivery. Our core business is focused on medical technologies in anesthesia, airway management, critical care and surgery.

We're dedicated to quality driven results.



SAFIRA™ is developed in line with international quality standards



All Medovate devices are manufactured in compliance with the highest FDA and international industry standards. Medovate is ISO 13485 certified.



What do leading anesthesiologists say?

According to 30 world leading regional anesthesiologists (EU & US):⁴

1/30

confident in their assistant applying the correct pressure⁴

2/30

confident they themselves could apply the correct pressure⁴

23/30

believed SAFIRA™ would allow them to save 5 (or more) minutes per procedure⁵

5 reasons to make the switch to SAFIRA™

SAFIRA™ gives anesthesiologists the tools to take control

1. SAFIRA - SAFer Injection for Regional Anesthesia

SAFIRA™ is a safer injection system for regional anesthesia, allowing a single anesthesiologist to conduct a whole regional block at safer pressures.

2. It makes regional anesthesia a one operator procedure

By giving anesthesiologists control of the whole procedure, they can manage all aspects of the regional block including injection of the anesthetic. This improves safety and frees up resource as a second supporting operator is no longer required.

3. It helps improve patient safety by controlling the injection pressure threshold

SAFIRA™ incorporates a safety feature to help prevent injection at pressures above 20psi. This reduces the risk of nerve damage in patients, promoting improved safety for regional anesthesia.

4. SAFIRA™ promotes better outcomes for patients

With its integrated safety solution to help limit the injection pressure threshold, SAFIRA™ can help reduce the risk of accidental nerve damage, omitting follow up procedures.¹ Minimising the risk of nerve damage also reduces the chance of potential lawsuits.

5. It saves time and reduces costs

SAFIRA™ saves 5 minutes per procedure⁵ and limits the costs associated with extra operators. When time is money, SAFIRA™ saves you both.

MEDOVATE

Developing Innovation

For more information about SAFIRA™
and appointed distributors contact us:

Email: enquiries@medovate.co.uk

Twitter: @Medovate

LinkedIn: Medovate Limited

medovate.co.uk

References

1. Heij R, Eldin E, Young P, Carter J, Gibson J, Ali A, et al. Regional Anesthesiology Injection Pressures comparing Skilled Assistants With SAFIRA in a Simulated Ultrasound Guided Technique. In: The Anesthesiology annual meeting [Internet]. 2013 [cited 2020 Mar 31]. Available from: <http://www.asaabstracts.com/strands/asaabstracts/abstract.htm?year=2013&index=17&absnum=3085>
2. Borgeat A, Blumenthal S. Nerve injury and regional anaesthesia [Internet]. Vol. 17, Current Opinion in Anaesthesiology. 2004 [cited 2020 Mar 31]. p. 417–21. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17023899>
3. Jeng CL, Torrillo TM, Rosenblatt MA. Complications of peripheral nerve blocks. Br J Anaesth [Internet]. 2010 [cited 2020 Mar 31];105(S1):97–107. Available from: https://academic.oup.com/bja/article-abstract/105/suppl_1/i97/235950
4. Health Enterprise East (HEE). Research results using a cohort of volunteer anaesthetists.
5. Fong-Soe-Khioe R. Health Economic report Medovate commissioned written by a health economist from the University of East Anglia (UEA).